EQS-Adhoc 109 0 Kommentare Vitruvia Medical AG: Year End results as of December 31, 2023

Für Sie zusammengefasst

Vitruvia Medical AG reported a net loss of CHF -243,864.40 in 2023, an improvement from the previous year.
Revenue increased to EUR 1,7575,724.00, with EBITA of EUR 61,078.00, compared to a loss in the previous year.
LT technologies met sales and profit expectations in 2023, with expectations for continued growth in 2024.

EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Annual Results/Annual Report
Vitruvia Medical AG: Year End results as of December 31, 2023

01-May-2024 / 08:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Vitruvia Medical AG: Year End results as of December 31, 2023

Anglikon, May 1^st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year.

On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00) and earnings before interest, taxes, depreciation and amortization (EBITA) of EUR 61,078.00, compared with EUR -912,086.00 in the previous year.

Earnings after taxes and amortization of goodwill amounted to EUR -535,435 compared with EUR -1,484,556 in the previous year

LT technologies has achieved its sales and profit expectations for 2023. For 2024, we expect LT technologies' activity to continue to pick up, which will be reflected in the sales and profit figures.

About Vitruvia Medical AG:

Vitruvia Medical AG is a Swiss investment company focusing on the repair, production and trade of medical devices as well as surgical instruments.

Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.

End of Inside Information

01-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Vitruvia Medical AG
	Kesselackerstr. 18
	5611 Anglikon
	Switzerland
Phone:	+41 44 915 33 78
E-mail:	kontakt@vitruvia-med.com
Internet:	www.vitruvia-med.com
ISIN:	CH0461931419
WKN:	A2PDWF
Listed:	Regulated Unofficial Market in Munich
EQS News ID:	1893569